Annual costs* and utilities for the model states
| Cost (range), in £ | Utility† | ||||
| Health state | Pathway | First year | Subsequent year | Utility value | Source |
| NMD+ | RSP | 183 | 158 | 0.88–0.91 | ref 23 31 |
| SC | 1223 | 65 | |||
| NMD− | RSP/SC | 0 | 0 | ||
| SLD+ | RSP | 1219 | 363 | 0.88–0.91 | ref 23 31 |
| SC | 1223 | 368 | |||
| SLD− | RSP/SC | 0 | 0 | ||
| CC+ | RSP | 1721 (1651–1791) | 921 (887–956) | 0.78–0.81 | ref 23 31 50 |
| SC | 1725 (1656–1795) | 884 (850–919) | |||
| CC− | RSP/SC | 0 | 0 | 0.88–0.91 | ref 23 31 |
| DC | 6672 (4221–9123) | 7706 (5525–9887) | 0.66 (95% CI 0.46 to 0.86) | ref 32 | |
| HCC | 19 414 (19 151–19 678) | 18 172 (17 909–18 436) | 0.65 (95% CI 0.44 to 0.86) | ||
| Transplant | 89 282 (56 301–184 574) | 20 687 (15 549–25 452) | 0.69 (95% CI 0.62 to 0.77) | ||
*The details with data sources for costs are in online supplementary appendix 4. We used triangular or uniform distribution to encompass uncertainty around expert opinions, where triangular distribution was used in the cases in which the most likely estimate was identified.
†We used beta distribution for DC, HCC and transplant utilities; normal distribution was used for coefficients in the regression equation used to calculate utilities for NMD, SLD and CC states.
CC, compensated cirrhosis; DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; NMD, no/mild disease; RSP, risk stratification pathway; SC, standard care; SLD, significant liver disease.